(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.04%) $0.927
(0.00%) $10.84
(-0.11%) $0.791
(-0.21%) $92.38
@ $8.24
Issued: 14 Feb 2024 @ 15:41
Return: -6.38%
Previous signal: Feb 13 - 15:50
Previous signal:
Return: 3.45 %
Live Chart Being Loaded With Signals
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases...
Stats | |
---|---|
Today's Volume | 698 158 |
Average Volume | 1.24M |
Market Cap | 586.72M |
EPS | $0 ( 2024-02-15 ) |
Next earnings date | ( $-0.950 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.520 |
ATR14 | $0.00700 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-31 | Dube Eric M | Buy | 135 000 | Common Stock |
2024-02-01 | Dube Eric M | Sell | 9 106 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 360 000 | Employee stock option (right to buy) |
2024-02-01 | Dube Eric M | Sell | 10 016 | Common Stock |
2024-01-31 | Rote William E. | Buy | 25 000 | Common Stock |
INSIDER POWER |
---|
89.01 |
Last 100 transactions |
Buy: 2 015 500 | Sell: 112 292 |
Volume Correlation
Travere Therapeutics, Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Travere Therapeutics, Correlation - Currency/Commodity
Travere Therapeutics, Financials
Annual | 2023 |
Revenue: | $145.24M |
Gross Profit: | $88.86M (61.18 %) |
EPS: | $-1.500 |
Q4 | 2023 |
Revenue: | $45.06M |
Gross Profit: | $28.64M (63.57 %) |
EPS: | $-1.180 |
Q3 | 2023 |
Revenue: | $37.10M |
Gross Profit: | $35.81M (96.53 %) |
EPS: | $1.980 |
Q2 | 2023 |
Revenue: | $59.70M |
Gross Profit: | $57.71M (96.67 %) |
EPS: | $-1.130 |
Financial Reports:
No articles found.
Travere Therapeutics,
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators